15.6
Pharmakokinetisch-pharmakodynamische Beziehung: Probleme
Der empirische Ansatz zur Optimierung der Arzneimitteltherapie beruht auf der Korrelation der pharmakologischen Wirkung mit der verabreichten Dosis. D…
Die pharmakokinetisch–pharmakodynamische, oder PK–PD, Beziehung verbindet die pharmakologische Antwort mit der Wirkstoffkonzentration am Zielort, wie sie sich in den Plasmaspiegeln widerspiegelt.
Die Modellierung kann komplex werden, da racemische Mischungen, der Einfluss der Proteinbindung, die Verzögerung der Verteilung, die Bildung aktiver Metaboliten und die Entwicklung erworbener Toleranz entstehen.
Viele Medikamente werden als racemische Mischungen verabreicht, bei denen nur ein aktiver Isomer die Antwort antreibt, wodurch das Isomerverhältnis für die Wirksamkeit entscheidend ist.
Darüber hinaus korreliert die Arzneimittelantwort genauer mit der ungebundenen Plasmakonzentration, da die Proteinbindung die freien Arzneimittelspiegel verändert und die PK–PD-Modellierung erschwert.
Neben der Proteinbindung wirken viele Medikamente auf extravaskuläres Gewebe, was längere Gleichgewichtszeiten erfordert und die Reaktion verzögert.
Einige Medikamente produzieren pharmakologisch aktive Metaboliten im Körper. Die Plasmaspiegel dieser Metaboliten korrelieren möglicherweise besser mit der therapeutischen Wirkungskraft als die des Ausgangsmedikaments.
Außerdem kann chronischer Gebrauch einiger Medikamente zu erworbener Toleranz führen, entweder durch erhöhten Stoffwechsel oder durch eine verminderte Reaktion, was die PK–PD-Beziehung im Laufe der Zeit verändert.
View the full transcript and gain access to JoVE Core videos
Q1: Why is unbound drug concentration more important than total plasma concentration in PK-PD modeling?
Drug response correlates more accurately with unbound plasma concentration because protein binding alters free drug levels available to act at the target site. Total plasma concentration includes both bound and unbound drug, but only unbound drug can produce a pharmacological effect. Variations in protein binding between patients complicate PK-PD modeling when based solely on total concentration measurements.
Q2: How do active metabolites complicate the relationship between drug concentration and therapeutic response?
Some drugs produce pharmacologically active metabolites in the body whose plasma levels may correlate better with therapeutic response than the parent drug itself. Basing the PK-PD relationship solely on parent drug concentration can obscure the true concentration-response relationship. Examples include imipramine, amitriptyline, and propranolol, where metabolite activity significantly contributes to the overall therapeutic effect.
Q3: What causes delayed response in drugs acting on extravascular tissues?
Many drugs act on extravascular tissue rather than plasma, requiring longer equilibration times between the plasma and the site of action. This distribution delay means the pharmacological response lags behind plasma drug concentration changes. For example, the anticoagulant effect of dicoumarol shows long delays because it is an indirect measure of drug effect at the tissue level.
Q4: Why does the isomer ratio matter in racemic drug mixtures?
Many drugs are administered as racemic mixtures containing two optically active enantiomers, but typically only one active isomer drives the pharmacological response. A change in the ratio of active to inactive isomers can lead to significant differences in pharmacological response and efficacy. The isomer ratio is therefore crucial to predicting and maintaining consistent therapeutic outcomes.
Q5: How does acquired tolerance alter the PK-PD relationship over time?
Chronic use of some drugs may lead to acquired tolerance through either enhanced metabolism or diminished pharmacodynamic response. Pharmacokinetic tolerance involves increased drug elimination, while pharmacodynamic tolerance reflects reduced tissue responsiveness. Both mechanisms alter the PK-PD relationship, meaning the same plasma concentration may produce a weaker effect with repeated dosing.
Q6: What advantage does PK-PD modeling offer over empirical dose-response approaches?
PK-PD modeling correlates pharmacological response with plasma drug concentration or body drug amount rather than administered dosage, providing more precise predictions. Empirical approaches are costly, time-consuming, and often yield poor correlation due to formulation factors and drug elimination variability. Modeling assumes response is proportional to drug concentration at the site of action, reflected in plasma levels.
Q7: How does the duration of therapeutic action sometimes exceed plasma drug concentration persistence?
In some drugs like reserpine, the therapeutic action outlasts the measurable plasma drug concentration, creating a disconnect between plasma levels and observed effect duration. This occurs when drugs bind tightly to tissue receptors or produce sustained biochemical changes that persist after the drug is eliminated. Understanding this relationship is essential for predicting dosing intervals and the influence of elimination half-life on effect duration.